SGS to conduct its first malaria human challenge trial in Belgium

13 Feb 2019

The advanced candidate compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria.

SGS will commence its first malaria volunteer infection study (VIS) in Belgium in February 2019, on behalf of Medicines for Malaria Venture (MMV), a product development partnership (PDP) working in the field of antimalarial drug research. The study will assist in the development of an advanced candidate compound from the antimalarial drug pipeline developed by MMV and partners, which is a potential long-acting injectable chemoprotective drug.

SGS to conduct its first malaria human challenge trial in Belgium

The primary objective of the trial is to test the efficacy of MMV’s experimental compound in killing malaria parasites in the liver before they can develop and reach the bloodstream, thus protecting people from malarial disease. The trial will be conducted in SGS’ dedicated 20-bed unit at Antwerp’s Stuivenberg Hospital under a high level of safety and supervision.

“SGS is very proud to contribute to the global health effort to defeat malaria in the world. The malaria parasite killed 435,000 people in 2017 and infected an estimated 219 million. Fifty percent of the world’s population are living in over 90 countries where malaria transmission occurs. Ninty-one percent of the deaths are in Africa in predominantly low-income regions. Young children and pregnant women form an especially vulnerable group, associated with a high rate of mortality and as such urgently need novel treatments. This has led to a decision by SGS to step into the field of antimalarial drug development,” commented Adrian Wildfire, Project Director, Infectious Diseases and Human Challenge Unit at SGS.

Dr Pieter-Jan Berghmans, Investigator at SGS and Principal Investigator of the trial, continued: “As there is a continued risk of resistance to currently marketed drugs, developing new antimalarial drugs is a high priority.”

“MMV and its partners have taken a leadership role in finding new ways to accelerate the development of new medicines to treat and prevent malaria. The compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria, and could therefore help protect children from becoming ill. In collaboration with SGS, this potential treatment will be tested in human subjects for the first time,” said Dr Timothy Wells, MMV’s Chief Scientific Officer.

Read More

Related news

HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad launches anti-certolizumab pegol antibodies

5 May 2020

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

Read more 
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

Read more 
AstraZeneca incredibly excited by lung cancer treatment trial

AstraZeneca "incredibly excited" by lung cancer treatment trial

13 Apr 2020

Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.

Read more 
German pharma companies are meeting the corona stress test

German pharma companies are meeting the corona "stress test"

7 Apr 2020

The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.

Read more 
World’s leading biobanks join a global network to advance personalized healthcare research

World’s leading biobanks join a global network to advance personalized healthcare research

6 Apr 2020

The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

Read more 
Servier strengthens its R&D pipeline with Symphogen acquisition

Servier strengthens its R&D pipeline with Symphogen acquisition

6 Apr 2020

Symphogen becomes the antibody center of excellence within Servier.

Read more